HLA-A and HLA-B belong to MHC class I antigens, and former research have shown that abnormal MHC-I expression and function regulation may be hijacked by tumor cells to evade immune surveillance, thereby promoting tumor progression and impairing the efficacy of cancer immunotherapy (45–47). The gene discussed is HLA-B; the disease is cancer.